StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
IMH-R.BK$2.92+0.00%
Fair $2.92+0.0%

IMH-R.BK

Intermedical Care and Lab Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$2.92

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.92Fund rank 27/100 · Data gapFallback financials|
SA 17/F
F-Score: 3/9
Margin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $84.8M · quality 48.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 59/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Operating margin has declined for 3 consecutive years ROE is -34.8%, below the 5% threshold
Thesis & Journal · IMH-R.BKLocal privado en este navegador · Intermedical Care and Lab Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$692M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-34.8%

↓

Gross Margin

13.5%

↓

Debt/Equity

1.99

↑
52-Week Range$3
$4$9

TradingView lightweight chart

IMH-R.BK price, volumen y niveles de valoración

Último $4.260Periodo +63.8%
Fair value: $2.920

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+5.7%

FCF CAGR

+50.9%

FCF margin

16.1%

FCF / Net income

-0.65x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $754.9M · net income $-188.7M · FCF $121.8M

2022-FY → 2025-FY

Gross margin

13.5%-38.9% pts

Operating margin

-16.7%-51.4% pts

Net margin

-25.0%-52.1% pts

FCF margin

16.1%+10.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$754.9M$754.9M$756.0M$669.6M$639.8M
Net Income$-188.7M$-188.7M$-99.8M$19.1M$173.1M
EBITDA$-70.3M$-70.3M$14.7M$113.3M$257.8M
EPS-0.84-0.84-0.470.090.81
Gross Margin13.5%13.5%18.2%35.7%52.4%
Operating Margin-16.7%-16.7%-6.0%15.3%34.7%
Net Margin-25.0%-25.0%-13.2%2.9%27.1%
Balance Sheet
Debt/Equity1.991.991.721.600.21
Current Ratio0.400.40———
Cash Flow
Free Cash Flow$121.8M$121.8M$84.8M$64.6M$35.5M
Returns
ROE-34.8%-34.8%-14.6%2.5%20.9%
Valuation
P/E———97.8615.06
EV/EBITDA——206.7326.9910.20
P/B1.221.222.762.433.15
Growth & Yield
Revenue Growth-0.1%-0.1%12.9%4.7%—
EPS Growth-78.7%-78.7%-622.2%-88.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -51.6%

Total return

-51.6%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.47 → -0.84

Residual

-51.6%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-51.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.